These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38499765)

  • 1. Metformin and feeding increase levels of the appetite-suppressing metabolite Lac-Phe in humans.
    Scott B; Day EA; O'Brien KL; Scanlan J; Cromwell G; Scannail AN; McDonnell ME; Finlay DK; Lynch L
    Nat Metab; 2024 Apr; 6(4):651-658. PubMed ID: 38499765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lac-Phe mediates the effects of metformin on food intake and body weight.
    Xiao S; Li VL; Lyu X; Chen X; Wei W; Abbasi F; Knowles JW; Tung AS; Deng S; Tiwari G; Shi X; Zheng S; Farrell L; Chen ZZ; Taylor KD; Guo X; Goodarzi MO; Wood AC; Chen YI; Lange LA; Rich SS; Rotter JI; Clish CB; Tahir UA; Gerszten RE; Benson MD; Long JZ
    Nat Metab; 2024 Apr; 6(4):659-669. PubMed ID: 38499766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.
    Derosa G; Mereu R; Salvadeo SA; D'Angelo A; Ciccarelli L; Piccinni MN; Ferrari I; Gravina A; Maffioli P; Cicero AF
    Intern Med; 2009; 48(5):265-71. PubMed ID: 19252346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
    Toft-Nielsen MB; Madsbad S; Holst JJ
    Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss.
    Day EA; Ford RJ; Smith BK; Mohammadi-Shemirani P; Morrow MR; Gutgesell RM; Lu R; Raphenya AR; Kabiri M; McArthur AG; McInnes N; Hess S; Paré G; Gerstein HC; Steinberg GR
    Nat Metab; 2019 Dec; 1(12):1202-1208. PubMed ID: 32694673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.
    Hirschberg Y; Karara AH; Pietri AO; McLeod JF
    Diabetes Care; 2000 Mar; 23(3):349-53. PubMed ID: 10868864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin increases plasma ghrelin in Type 2 diabetes.
    Doogue MP; Begg EJ; Moore MP; Lunt H; Pemberton CJ; Zhang M
    Br J Clin Pharmacol; 2009 Dec; 68(6):875-82. PubMed ID: 20002081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin.
    Osonoi T; Saito M; Hariya N; Goto M; Mochizuki K
    Peptides; 2016 Dec; 86():118-125. PubMed ID: 27780736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-load hyperglycaemia-an inappropriate therapeutic target.
    Yudkin JS
    Lancet; 2002 Jan; 359(9301):166-7. PubMed ID: 11809285
    [No Abstract]   [Full Text] [Related]  

  • 10. [Fasting hyperglycemia and postprandial glucose peaks. Diabetes therapy mustact on 2 sides].
    MMW Fortschr Med; 2003 Aug; 145(33-34):59. PubMed ID: 14526583
    [No Abstract]   [Full Text] [Related]  

  • 11. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of efficacy and tolerability of gliclazide and metformin combination: a multicentric study in patients with type 2 diabetes mellitus uncontrolled on monotherapy with sulfonylurea or metformin.
    Pareek A; Chandurkar N; Zawar S; Agrawal N
    Am J Ther; 2010; 17(6):559-65. PubMed ID: 20093927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes.
    Gastaldelli A; Nauck MA; Balena R
    Metabolism; 2013 Sep; 62(9):1330-9. PubMed ID: 23831441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective, parallel group, open-labeled, comparative, multi-centric, active controlled study to evaluate the safety, tolerability and benefits of fixed dose combination of acarbose and metformin versus metformin alone in type 2 diabetes.
    Jayaram S; Hariharan RS; Madhavan R; Periyandavar I; Samra SS
    J Assoc Physicians India; 2010 Nov; 58():679-82, 687. PubMed ID: 21510461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin prolongs the postprandial fall in plasma ghrelin concentrations in type 2 diabetes.
    English PJ; Ashcroft A; Patterson M; Dovey TM; Halford JC; Harrison J; Eccleston D; Bloom SR; Ghatei MA; Wilding JP
    Diabetes Metab Res Rev; 2007 May; 23(4):299-303. PubMed ID: 16952199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restoring post-prandial insulin release in type 2 diabetes.
    Andrews J
    Hosp Med; 2002 Feb; 63(2):95-8. PubMed ID: 11902096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes.
    Preiss D; Dawed A; Welsh P; Heggie A; Jones AG; Dekker J; Koivula R; Hansen TH; Stewart C; Holman RR; Franks PW; Walker M; Pearson ER; Sattar N;
    Diabetes Obes Metab; 2017 Mar; 19(3):356-363. PubMed ID: 27862873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
    Forst T; Anastassiadis E; Diessel S; Löffler A; Pfützner A
    Diabetes Metab Res Rev; 2014 Oct; 30(7):582-9. PubMed ID: 24459063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin: an antihyperglycemic drug for non-insulin-dependent diabetes mellitus.
    Kupecz D
    Nurse Pract; 1995 Jul; 20(7):70-2. PubMed ID: 7675343
    [No Abstract]   [Full Text] [Related]  

  • 20. Metformin-associated prevention of weight gain in insulin-treated type 2 diabetic patients cannot be explained by decreased energy intake: A post hoc analysis of a randomized placebo-controlled 4.3-year trial.
    Out M; Miedema I; Jager-Wittenaar H; van der Schans C; Krijnen W; Lehert P; Stehouwer C; Kooy A
    Diabetes Obes Metab; 2018 Jan; 20(1):219-223. PubMed ID: 28681986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.